JPH05306286

• Main Authors: TAKAMURA NORIO, MATSUOKA YUZO, IWATA HIROSHI, YASUNAKA MASAYUKI, YASUDA KOUSUKE
• Format: Patent
• Language: English
• Published: 19.11.1993
• Edition: 5
• Subjects: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM; CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PURPOSE:To provide the subject new compound having excellent cholinesterase- inhibitory activity, suitable for curing or preventing various diseases due to the decline in cholinergic functions, esp. Arzheimer-type senile dementia because of its large maximum tolerance dose and low toxicity. CONSTITUTION:The objective compound of formula I [R is H, aminocarbonyl, etc.; R is lower alkyl; X and X are such that one of them is S, the other being of formula II (R is the same as R ); n is 1 or 2] or a salt thereof, e.g. a compound of formula III. The compound of the formula I can be obtained by the following process: a compound of formula IV (R is the same as R except H; R is thiol-protecting group) is made to react with a lower alkyl halide to form a compound of formula V, which is then dethiolated through e.g. zinc-acetic acid treatment followed by reaction with a compound of formula Br-(CH2)n+1-X (X is halogen), and the resulting intermediate is made to react with an alkali metal salt of thio-lower alkanoic acid to produce a compound of formula VI (R is lower alkanoyl), which is finally put to intramolecular ring closure in the presence of a reducing agent such as metallic sodium.